# Study of DA-9801 to Treat Diabetic Neuropathy

> **NCT01822925** · PHASE2 · COMPLETED · sponsor: **NeuroBo Pharmaceuticals Inc.** · enrollment: 128 (actual)

## Conditions studied

- Diabetic Neuropathy

## Interventions

- **DRUG:** DA-9801 300mg
- **DRUG:** DA-9801 600mg
- **DRUG:** DA-9801 900mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01822925
- **Lead sponsor:** NeuroBo Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2015-01
- **Final completion:** 2015-01
- **Target enrollment:** 128 (ACTUAL)
- **Last updated:** 2020-03-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01822925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01822925, "Study of DA-9801 to Treat Diabetic Neuropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01822925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*